/

Mirati Therapeutics, Inc.

MRTX US

MRTX USMirati Therapeutics, Inc.

United States Composite

58.89

USD

+0.01

(+0.02%)

-12.12EPS Dil.

-4.86P/E

4.13BMarket Cap

Next Earnings

February 26

Held by Insiders

1.72%

Held by Institutions

117.76%

Short % of Float

6.26%

YTD Yield

33.81%

3Y Yield

-64.57%

Capital Structure

FRC

•

in mil. unless spec.

Mar'23

Jun'23

Sep'23

ST Debt

LT Borrowings

- -

LT Finance Leases

Preferred Equity and Hybrid Capital

- -

Shares Outstanding

Market Capitalization

2,163

2,108

3,054

Working Capital

FRC

•

in mil. unless spec.

Mar'23

Jun'23

Sep'23

Total Current Assets

939

819

1,036

Cash, Cash Equivalents & STI

902

779

976

Accounts Receivable, Net

Inventories

Total Current Liabilities

125

140

137

Payables & Accruals

125

ST Debt

Deferred Revenue

- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years

5 years

1 year

Sales/Revenue/Turnover

- -

-83.33%

Net Income, GAAP

-52.31%

-63.06%

-27.32%

Free Cash Flow

-46.44%

-58.89%

-44.11%

Total Cash Common Dividend

- -

Total Equity

80.48%

72.13%

-28.63%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

2021

- -

2022

2023

- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

2021

-2.67

-3.23

-1.55

-3.73

-11.23

2022

-3.40

-3.19

-3.09

-3.51

-13.18

2023

-3.15

-3.04

-2.49

- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

2021

- -

2022

- -

2023

- -

Company Description

CEO: Dr. Charles M. Baum M.D., Ph.D.
Full Time Employees: 587
Sector: Healthcare
Industry: Biotechnology
Address: 3545 Cray Court San Diego CA United States 92121
CIK: 0001576263
Website: www.mirati.com
Business: Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. In addition, the company pipeline comprises the MRTX1719, an investigational synthetic lethal PRMT5 inhibitor designed to target the PRMT5/methylthioadensoine (MTA) complex and is in clinical development; MRTX0902, a selective SOS1 inhibitor that improves anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors, and is in clinical development; and MRTX1133, an investigational lead KRAS G12D compound. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and Zai Lab Ltd. to research, develop, manufacture, and commercialize adagrasib in various indications. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.

Company Description

CEO: Dr. Charles M. Baum M.D., Ph.D.
Full Time Employees: 587
Sector: Healthcare
Industry: Biotechnology
Address: 3545 Cray Court San Diego CA United States 92121
CIK: 0001576263
Website: www.mirati.com
Business: Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. In addition, the company pipeline comprises the MRTX1719, an investigational synthetic lethal PRMT5 inhibitor designed to target the PRMT5/methylthioadensoine (MTA) complex and is in clinical development; MRTX0902, a selective SOS1 inhibitor that improves anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors, and is in clinical development; and MRTX1133, an investigational lead KRAS G12D compound. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and Zai Lab Ltd. to research, develop, manufacture, and commercialize adagrasib in various indications. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.